Overview of a promising new study of venetoclax in patients with CLL
The next steps and updated guidelines for the use of MRD concepts in multiple myeloma
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
Arnon Nagler et al.
Challenges associated with long-term therapies in CLL
What’s new in minimal residual disease (MRD) detection in myeloma?